Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment

Hepatitis C Virus Dynamic and Immune Activation in HIV-1 Coinfected Patients Treated With Pegylated Interferon Alfa-2a and Ribavirin

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00909129

Acronym

DICO

Enrollment

Registered

2009-05-27

Start date

Unknown

Completion date

Unknown

Last updated

2009-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C, Human Immunodeficiency Virus

Keywords

HIV-1, Chronic hepatitis C, Immune activation, HCV kinetics, IP-10

Brief summary

The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV and determine how these responses are affected by HCV treatment and correlates to response. Furthermore, to study Interferon-inducible protein-10 (IP-10) dynamics during HCV treatment, and correlate this to treatment outcome.

Interventions

DRUGpegylated interferon-alpha (Pegasys)

Pegylated interferon-alpha 2a 180 micrograms s.c. weekly

DRUGribavirin (COPEGUS)

ribavirin bid 800-1200 mg depending on HCV genotype and body weight

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* HIV-1 Hepatitis C coinfected adult patients * Hepatitis C treatment naive * Stable HIV-1 infection with or without cART * \> 300 CD4+ cell count

Exclusion criteria

* Decompensated liver disease * Ongoing depression * Ongoing drug abuse * Other contraindications for interferon or ribavirin treatment

Design outcomes

Primary

Measure	Time frame
Sustained virological response	24 weeks end of treatment (EOT)

Secondary

Measure	Time frame
T-cell mediated immune responses	baseline to 24 weeks EOT

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026